Sirolimus inhibits the mTOR pathway, crucial for B- and T-lymphocyte proliferation, offering targeted immunosuppression beneficial in immune dysregulation disorders like ITP, as highlighted in recent literature [15, 16]. This evidence concerns the gene MTOR and autoimmune thrombocytopenic purpura.